BIIB - バイオジェン (Biogen Inc.) バイオジェン

 BIIBのチャート


 BIIBの企業情報

symbol BIIB
会社名 Biogen Inc (バイオジェン)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 医薬品   医療関連(Health Care)
概要 事業概要 バイオジェン(Biogen Inc.)は生物技術会社である。同社は神経学的疾患、希少疾患、自己免疫疾患の治療製品の発見・開発・製造・提供に従事する。同社は多発性硬化症(MS)の治療用「ECFIDERA」、「AVONEX」、「PLEGRIDY」、「TYSABRI」、「ZINBRYTA」、「FAMPYRA」、重症プラーク乾癬の治療用「FUMADERM」、脊髄性筋萎縮症(SMA)の治療用「SPINRAZA」を含む製品を販売する。同社はまた非ホジキンリンパ腫、慢性リンパ球性白血病(CLL)等の治療用「RITUXAN」に関連するRoche GroupのメンバーであるGenentech、Inc.(Genentech)との共同契約を締結して、CLLと濾胞性リンパ腫の治療用「GAZYVA」、他の抗CD20療法を提供する。同社は製品候補はOCREVUS、バイオシミラー・アダリムマブ、Aducanumab、E2609、BIIB074、BAN2401、オピシヌマブ、CIARA、BIIB061、BIIB054、BIIB067、BIIB068を含む。   バイオジェンはバイオ医薬品企業。神経疾患治療の医薬品の開発・製造・販売に従事する。再発性多発性硬化症(MS)治療薬、クロ―ン病治療薬、非ホジキンリンパ腫と関節リウマチ治療薬などが主要製品。また、潰瘍性大腸炎などの自己免疫疾患のほか、血友病、リンパ性白血病、非ホジキンリンパ腫の治療薬も扱う。本社はマサチュ―セッツ州ケンブリッジ。   Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
本社所在地 225 Binney Street Cambridge MA 02142 USA
代表者氏名 Stelios Papadopoulos Stelios Papadopoulos
代表者役職名 Independent Chairman of the Board
電話番号 +1 781-464-2000
設立年月日 31229
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 7300人
url www.biogen.com
nasdaq_url https://www.nasdaq.com/symbol/biib
adr_tso
EBITDA EBITDA(百万ドル) 6760.6
終値(lastsale) 343.03
時価総額(marketcap) 69100940835.5
時価総額 時価総額(百万ドル) 69411.16
売上高 売上高(百万ドル) 12872.4
企業価値(EV) 企業価値(EV)(百万ドル) 72115.36
当期純利益 当期純利益(百万ドル) 4141.8
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Biogen Inc revenues increased 10% to $6.49B. Net income increased 27% to $2.04B. Revenues reflect Product net increase of 5% to $5.28B Revenue Sales of Goods_Services increase of 27% to $933.6M Other Rev from Biz Related Activ. increase from $131.6M to $273M. Net income benefited from Amortization of acquired intangible asse decrease of 63% to $211.3M (expense).

 BIIBのテクニカル分析


 BIIBのニュース

   Dr Reddy's enters Rs 28,000 cr market with multiple sclerosis drug in US  2020/09/26 12:37:00 Business Standard
The company's product is a therapeutic equivalent generic version of Biogen's Tecfidera delayed-release capsules, the Hyderabad-based drug firm said in a statement
   Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020: Comprehensive Listing of 2,300+ Clinical Stage Partnering Deals  2020/09/18 17:30:00 Benzinga
DUBLIN , Sept. 18, 2020 /PRNewswire/ -- The "Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020" report has been added to ResearchAndMarkets.com's offering. The Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020 report provides a detailed understanding and analysis of how and why companies enter clinical stage partnering deals and provides details of the latest clinical agreements announced in the healthcare sector. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not. This report contains a comprehensive listing of over 2,300 clinical stage partnering deals announced since 2014 including financial terms where available including numerous links to online deal records of actual clinical partnering deals as disclosed by the deal parties.
   Delaware judge deals Biogen another blow in Tecfidera patent fight  2020/09/16 22:14:35 Reuters
A federal judge in Delaware on Wednesday dealt another setback to drug company Biogen Inc in its effort to keep generic versions of its multiple sclerosis treatment Tecfidera off the market through patent litigation.
   Biogen on losing end of Tecfidera patent infringement case in Delaware (NASDAQ:BIIB)  2020/09/16 14:25:12 Seeking Alpha
Posts on social media say that Biogen (BIIB +1.2%) has lost its patent infringement lawsuit in Delaware related to top seller Tecfidera (dimethyl fumarate)
   Morgan Stanley handpicked the 10 best healthcare stocks to buy now as investors brace for a major election and the potential for another coronavirus surge  2020/09/15 12:00:00 Business Insider
Summary List Placement Two big questions are looming in the coming months: Who will win the US presidential election? And how quickly will the world will emerge from the coronavirus pandemic? Republican President Donald Trump is campaigning for a second term against his Democratic opponent, Joe Biden. Aside from the coronavirus pandemic, among the biggest uncertainties for healthcare companies are the future of the Affordable Care Act — including whether lawmakers will move to expand government health insurance — and how politicians will crack down on drug prices. "Healthcare is one of the sectors that could be most impacted by policy coming out of the upcoming election," Morgan Stanley analysts wrote in a note published Monday. Read more: Meet the 24 most powerful people advising Trump on healthcare as the president vies for a second term The analysts predict that, in the months ahead, the US will see a faster reopening of the economy as people adapt to new ways of living and of buying the products they need.
   Tech Stock Buybacks Are Surging  2020/08/03 00:46:15 Zero Hedge
Tech Stock Buybacks Are Surging Tyler Durden Sun, 08/02/2020 - 20:46 Two months ago, we showed that contrary to conventional wisdom and corporate reps and warrants that buybacks had effectively been put on hold for the duration of the covid pandemic, not only were companies still repurchasing their shares but it was the tech names - those who have stormed higher since the March lows - that were the biggest culprits. Now, two months after we first revealed Wall Street's worst kept secret, the Financial Times has also noticed that Corporate America is finding it hard to kick the share buyback habit, even after the US slipped into its worst recession in decades. While total buybacks are indeed expected to drop this year as the downturn caused by coronavirus saps corporate profits, companies in the S&P 500 that have reported second-quarter earnings so far have reduced the number of their outstanding shares by an average of 0.3 per cent from the previous quarter, according to calculations from Credit Suisse.
   Morning Bell With Jim Cramer: Don't Buy Biogen Shares  2020/07/23 13:52:16 The Street
Jim Cramer shares stock market news including why investors shouldn't buy Biogen, Slack's dispute with Microsoft, and why someone is buying airline stocks.
   Biogen Earnings: BIIB Stock Jumps 1% Higher on Q2 Beats  2020/07/22 15:44:07 InvestorPlace
Biogen earnings on Wednesday have BIIB stock higher after the company crushed Wall Street's expectations for EPS and revenue for the quarter.
   Biogen Inc. (BIIB) Q2 2020 Earnings Call Transcript | AlphaStreet  2020/07/22 15:37:20 News Alphastreet
Biogen Inc. (NASDAQ: BIIB) Q2 2020 earnings call dated July 22, 2020 Presentation: Operator Good morning. My name is Regina, and I'll be your conference
   Biogen Beats Earnings Expectations but Leaves CFO’s Departure a Mystery  2020/07/22 13:02:00 Barron's
Why did the company announce the departure of its chief financial officer on the evening before the earnings call?
   Biogen, Eisai Start New Phase 3 Trial For Pre-clinical Alzheimer’s Disease  2020/07/14 11:37:55 Smarter Analyst
Biogen (BIIB), in collaboration with Eisai, and the Alzheimer’s Clinical Trials Consortium, has initiated a new global Phase 3 clinical study (AHEAD 3-45) … The post Biogen, Eisai Start New Phase 3 Trial For Pre-clinical Alzheimer’s Disease appeared first on Smarter Analyst .
   Eisai and Biogen launch Phase 3 BAN2401 program in asymptomatic alzheimer's disease (OTCMKTS:ESALF)  2020/07/14 10:17:23 Seeking Alpha
Eisai (OTCPK:ESALF) in collaboration with Alzheimer's Clinical Trials Consortium and Biogen (NASDAQ:BIIB) has initiated a new global Phase 3 clinical study
   Initiation Of New Phase III Clinical Study (AHEAD 3-45) Of BAN2401 Preclinical (Asymptomatic) Alzheimer's Disease  2020/07/13 23:31:00 PR Newswire
TOKYO and CAMBRIDGE, Mass., July 13, 2020 /PRNewswire/ -- The Alzheimer's Clinical Trials Consortium (ACTC), Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"), and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos,…
   Potential Alzheimer's Drug Not Enough to Excite Biogen Stock Investors  2020/07/10 12:23:01 InvestorPlace
Biogen opened higher by around 10% on news of its Alzheimer's drug. By the end of day, Biogen stock gave up a bulk of its gains. What gives?
   4 Top Stock Trades for Thursday: TWTR, NIO, BIIB, SNAP  2020/07/08 20:56:55 InvestorPlace
Snap, Nio, Biogen and Twitter were our top stock trades for Thursday. That said, let's see how the charts are setting up after some big moves.

 関連キーワード  (医薬品 米国株 バイオジェン BIIB Biogen Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)